ArticleFrontiers of medicine2022

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.

Sisi Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.